Please assess the completion status of the following clinical trial:

Trial Title: A Study to Observe Characteristics of Rheumatoid Arthritis in Patients Using Infliximab (Study P04250)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subject has been diagnosed with RA~* Physician has decided, with the subject's consent, to begin treatment with infliximab~* Written informed consent form signed by both the subject and the physician.~Exclusion Criteria:~* Subjects who have previously been exposed to infliximab

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RA Subjects/ Infliximab 3 mg/kg (Type: None): Subjects with rheumatoid arthritis (RA) in whom treatment with infliximab is started for the first time, in line with current clinical practice (and thus consistent with the European Summary of Product Characteristics \[SPC\] of Remicade®).

Based on this trial design, predict the completion outcome and termination type (if applicable).